Your browser doesn't support javascript.
loading
Alteration in the sensitivity to crizotinib by Na+/H+ exchanger regulatory factor 1 is dependent to its subcellular localization in ALK-positive lung cancers.
Yang, Fenglian; Hu, Mu; Chang, Siyuan; Huang, Jing; Si, Yang; Wang, Jinghui; Cheng, Shan; Jiang, Wen G.
Afiliação
  • Yang F; School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, People's Republic of China.
  • Hu M; Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, China.
  • Chang S; Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, China.
  • Huang J; Department of Thoracic Surgery, Beijing Xuanwu Hospital, Beijing, 100053, P.R. China.
  • Si Y; School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, People's Republic of China.
  • Wang J; Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, China.
  • Cheng S; School of Basic Medical Sciences, Capital Medical University, Beijing, 100069, People's Republic of China.
  • Jiang WG; Beijing Key Laboratory of Cancer & Metastasis Research, Capital Medical University, Beijing, China.
BMC Cancer ; 20(1): 202, 2020 Mar 12.
Article em En | MEDLINE | ID: mdl-32164629
ABSTRACT

BACKGROUND:

Na+/H+ exchanger regulatory factor 1 (NHERF1) is an important scaffold protein participates in the modulation of a variety of intracellular signal pathways. NHERF1 was able to enhance the effects of chemo-drugs in breast and cervical cancer cells. Anaplastic lymphoma kinase (ALK) fusion mutations are validated molecules targeted therapy in lung cancers, where crizotinib can be used as the specific inhibitor to suppress tumor progression. However, due to the less frequent occurrence of ALK mutations and the complexity for factors to determine drug responses, the genes that could alter crizotinib sensitivity are unclear.

METHODS:

Both ALK-translocated and ALK-negative lung adenocarcinoma specimens in tissue sections were collected for immunohistochemistry. The possible mechanisms of NHERF1 and its role in the cell sensitivity to crizotinib were investigated using an ALK-positive and crizotinib-sensitive lung adenocarcinoma cell line H3122. Either a NHERF1 overexpression vector or agents for NHERF1 knockdown was used for crizotinib sensitivity measures, in association with cell viability and apoptosis assays.

RESULTS:

The expression level of NHERF1 in ALK-translocated NSCLC was significantly higher than that in other lung cancer tissues. NHERF1 expression in ALK positive lung cancer cells was regulated by ALK activities, and was in return able to alter the sensitivity to crizotinib. The function of NHERF1 to influence crizotinib sensitivity was depending on its subcellular distribution in cytosol instead of its nucleus localized form.

CONCLUSION:

Ectopically overexpressed NHERF1 could be a functional protein for consideration to suppress lung cancers. The determination of NHERF1 levels in ALK positive NSCLC tissues might be useful to predict crizotinib resistance, especially by distinguishing cytosolic or nuclear localized NHERF1 for the overexpressed molecules.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Regulação para Cima / Trocadores de Sódio-Hidrogênio / Carcinoma Pulmonar de Células não Pequenas / Crizotinibe / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fosfoproteínas / Regulação para Cima / Trocadores de Sódio-Hidrogênio / Carcinoma Pulmonar de Células não Pequenas / Crizotinibe / Quinase do Linfoma Anaplásico / Neoplasias Pulmonares Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article